Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 22 June 2010
Vol. 3, Issue 127, p. ec188
[DOI: 10.1126/scisignal.3127ec188]

EDITORS' CHOICE

Neuroscience A Postreceptor Intervention

Elizabeth M. Adler

Science Signaling, AAAS, Washington, DC 20005, USA

Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs), which increase synaptic concentrations of serotonin, are the most widely used class of antidepressant medications. Both the antidepressant activity of the SSRIs and their untoward side effects are thought to involve activation of 5-HT1 receptors, a class of G protein–coupled receptors (GPCRs) that signal through the G{alpha}i/o family of heterotrimeric guanine nucleotide–binding proteins. Noting that in vitro data suggest that 5-HT1 receptors preferentially interact with G{alpha}i2, Talbot et al. explored the effects in knock-in mice of a point mutation in G{alpha}i2 (G{alpha}i2G184S) that disrupts G{alpha}i2 association with regulator of G protein signaling (RGS) proteins and would thereby be expected to prolong its activity. Compared with wild-type littermates, mice homozygous or heterozygous for G{alpha}i2G184S showed antidepressant-like behavior (decreased immobility in tail suspension and forced-swim tests), effects that were reversed by the 5-HT1A antagonist WAY 100635. Similarly, G{alpha}i2G184S/G184S mice showed reduced novelty-induced hypophagia (consistent with the behavior of mice chronically administered antidepressants), as well as behaviors consistent with anxiolytic activity. The heterozygous G{alpha}i2G184S/+ mice showed increased sensitivity to the antidepressant-like effects of the 5-HT1A agonist 8-OH-DPAT and the SSRI fluvoxamine (assessed by immobility in the tail suspension test) but not to 8-OH-DPAT–induced hypothermia or to the behavioral effects of non-SSRI antidepressants. Phosphorylation of glycogen synthase kinase-3β (GSK3β) on Ser9 has been implicated in the behavioral effects of the SSRIs, and knock-in mice showed increased basal GSK3β Ser9 phosphorylation in cortex and hippocampus, an effect that was lost when they were treated with WAY 100635. The authors propose that modulation of 5-HT1A receptor–associated G{alpha}i2 activity—either through functionally selective 5-HT1A agonists or by targeting the appropriate population of RGS proteins—could thus conceivably provide a more selective approach to antidepressant therapy.

J. N. Talbot, E. M. Jutkiewicz, S. M. Graves, C. F. Clemans, M. R. Nicol, R. M. Mortensen, X. Huang, R. R. Neubig, J. R. Traynor, RGS inhibition at G{alpha}i2 selectively potentiates 5-HT1A–mediated antidepressant effects. Proc. Natl. Acad. Sci. U.S.A. 107, 11086–11091 (2010). [Abstract] [Full Text]

Citation: E. M. Adler, A Postreceptor Intervention. Sci. Signal. 3, ec188 (2010).



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882